研究者業績

藤原 慎一郎

フジワラ シンイチロウ  (Shinichiro Fujiwara)

基本情報

所属
自治医科大学 輸血・細胞移植部 教授

J-GLOBAL ID
201401051157883889
researchmap会員ID
B000237458

外部リンク

論文

 153
  • Yumiko Toda, Ken Ohmine, Naoki Sano, Naoya Nakamura, Atsushi Kihara, Ryutaro Tominaga, Atsuto Noguchi, Daizo Yokoyama, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Kento Umino, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Shin-Ichiro Fujiwara, Yoshinobu Kanda
    Pathology, research and practice 263 155600-155600 2024年11月  
    Rapidly progressing ALL, a potentially fatal disease, demands timely diagnosis and treatment. On the other hand, spontaneous remission/regression (SR) is reported in various cancers including aggressive tumors like ALL. Infection or trauma-mediated immune system activation is assumed to cause SR, with the duration in cases of ALL typically being short. Indolent T-lymphoblastic proliferation (i-TLP) exhibits the uniform proliferation of TdT-positive T-cells, despite being a non-neoplastic disease, underscoring the significance of distinguishing it from T-cell acute lymphoblastic leukemia (T-ALL). i-TLP is expected to gain wider recognition and further advancements in understanding its pathology. Here, we present the case of a 59-year-old woman with T-ALL characterized by cycles of progression and SR followed by a rapid blast proliferation. This is the first reported case of T-ALL with repeated SR for more than one year, making this case an extremely rare clinical presentation. This challenging case will enhance comprehension of T-cell tumor pathogenesis.
  • Tomoyasu Jo, Kyoko Yoshihara, Masaki Ri, Nobuhiro Tsukada, Naoya Mimura, Keiko Fujii, Kentaro Fukushima, Shin-ichiro Fujiwara, Yuji Shimura, Kyoko Haraguchi, Koji Kato, Atsushi Satake, Akiyo Yoshida, Rikio Suzuki, Junko Ikemoto, Keita Iwaki, Wataru Takeda, Noboru Yonetani, Ryuji Tanosaki, Minami Yamada-Fujiwara, Kaoru Kahata, Tokiko Nagamura-Inoue, Satoshi Yoshihara, Yasuyuki Arai
    Blood Neoplasia 100051-100051 2024年10月  
  • Toshiki Terao, Ken-ichi Matsuoka, Shigeo Fuji, Shunto Kawamura, Takashi Toya, Noriko Doki, Naoyuki Uchida, Masatsugu Tanaka, Takahiro Fukuda, Masashi Sawa, Jun Ishikawa, Tetsuya Nishida, Hiroyuki Ohigashi, Yumiko Maruyama, Shin-ichiro Fujiwara, Yoshinobu Kanda, Shuichi Ota, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Masao Ogata, Kimikazu Yakushijin, Hideki Nakasone
    Bone Marrow Transplantation 2024年5月25日  
  • Yutaka Shimazu, Junya Kanda, Kazuhito Suzuki, Akinori Wada, Taku Kikuchi, Takashi Ikeda, Nobuhiro Tsukada, Akiyoshi Miwa, Mitsuhiro Itagaki, Shinichi Kako, Kaichi Nishiwaki, Shuichi Ota, Shin-Ichiro Fujiwara, Keisuke Kataoka, Noriko Doki, Masashi Sawa, Nobuhiro Hiramoto, Akinori Nishikawa, Toshi Imai, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Koji Kawamura
    Cancer science 2024年5月16日  
    The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify the prognostic impact of Dara before ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent ASCT between 2017 and 2020. In the comparison between patients not administered Dara (Dara- group) and those administered Dara (Dara+ group), the 1-year progression-free survival (PFS) rates were 87.4% and 77.3% and the 1-year overall survival (OS) rates were 96.7% and 90.0%, respectively. In multivariate analysis, age <65 years (p = 0.015), low international staging system (ISS) stage (p < 0.001), absence of unfavorable cytogenic abnormalities (p < 0.001), no Dara use before ASCT (p = 0.037), and good treatment response before ASCT (p < 0.001) were independently associated with superior PFS. In matched pair analysis, the PFS/OS of the Dara- group were also significantly superior. For MM patients who achieved complete or very good partial response (CR/VGPR) by Dara addition before ASCT, both PFS and OS significantly improved. However, in patients who did not achieve CR/VGPR before ASCT, the PFS/OS of the Dara+ group were significantly inferior to those of the Dara- group.
  • Hiromi Hayashi, Makoto Iwasaki, Hideki Nakasone, Reo Tanoshima, Masashi Shimabukuro, Wataru Takeda, Tetsuya Nishida, Shinichi Kako, Shin-Ichiro Fujiwara, Yuta Katayama, Masashi Sawa, Kentaro Serizawa, Ken-Ichi Matsuoka, Naoyuki Uchida, Takashi Ikeda, Hiroyuki Ohigashi, Kentaro Fukushima, Moeko Hino, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Junya Kanda
    Cytotherapy 2023年12月16日  
    BACKGROUND AIMS: This study aimed to comprehensively assess the impact of stem cell selection between bone marrow (BM) and peripheral blood (PB) in unrelated hematopoietic stem cell transplantation (HSCT) for hematological malignancies. Our objective was to identify specific factors associated with better transplant outcomes. METHODS: A retrospective analysis was conducted using data from the Japanese HSCT registry. Inclusion criteria were patients aged 0-70 years who underwent their first unrelated HSCT with BM or PB, with an 8/8 or 7/8 allele HLA match for hematological malignancies between 2010 and 2020. RESULTS: Among 10 295 patients, no significant difference was observed in overall survival, relapse, graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) or non-relapse mortality between the groups. Patients who received PB showed no clear difference in acute GVHD but had a greater rate of chronic GVHD, resulting in poor chronic GVHD-free, relapse-free survival (CRFS). Subgroup analyses highlighted the importance of patient-specific factors in source selection. Patients with non-Hodgkin lymphoma and a greater hematopoietic cell transplantation-comorbidity index showed better CRFS and GRFS when BM was the preferred source. Similar trends were observed among patients with standard-risk disease for CRFS. However, no such trends were evident among patients aged 0-24 years, indicating that both sources are viable choices for young patients. CONCLUSIONS: This real-world retrospective analysis showed similar basic outcomes for BM and PB in an unrelated setting. The results support that BM may still be preferred over PB, especially when the long-term quality of life is a major concern. A consideration of individual factors can further optimize transplant success. Further research is warranted to explore the long-term implications of stem cell source selection.

MISC

 52

講演・口頭発表等

 3

共同研究・競争的資金等の研究課題

 4